ArticleExpert review of cardiovascular therapy2009
Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study.
Article in Expert review of cardiovascular therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02428374 (Role of Innate and Adaptive Immunity After Acute Myocardial Infarction BATTLE-AMI Study), which is not on this map. Cited by 9 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Role of Innate and Adaptive Immunity After Acute Myocardial Infarction BATTLE-AMI Study (B And T Types of Lymphocytes Evaluation in Acute Myocardial Infarction)
Who cites it
9 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Statins for the primary prevention of venous thromboembolism.The Cochrane database of systematic reviews · 2024Pooled it
- Statins for primary prevention of venous thromboembolism.The Cochrane database of systematic reviews · 2014Pooled it
- Statins for the primary prevention of cardiovascular disease.The Cochrane database of systematic reviews · 2013 · on this mapPooled it
- Endothelial Effect of Statin Therapy at a High Dose Versus Low Dose Associated with Ezetimibe.Arquivos brasileiros de cardiologia · 2016 · on this mapTrial
- A combined transcriptomics and proteomics approach reveals S100A4 as a potential biomarker for Graves' orbitopathy.Frontiers in genetics · 2024Article
- Statins for the Primary Prevention of Coronary Heart Disease.BioMed research international · 2019Article
- Cholesterol Serum Levels and Use of Statins in Graves' Orbitopathy: A New Starting Point for the Therapy.Frontiers in endocrinology · 2019Review
- Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease.JAMA ophthalmology · 2015Article
- Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective.Drug design, development and therapy · 2010 · on this mapReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) study was the first large-scale, prospective study to examine the benefits of statin therapy in subjects with elevated levels of high-sensitivity C-reactive protein but with low-to-normal LDL-cholesterol levels, who were not qualified for lipid-lowering treatment according to the current guidelines for primary prevention. The JUPITER study aimed to determine whether rosuvastatin 20 mg daily would reduce the rate of first major cardiovascular events, including cardiovascular death, nonfatal stroke, nonfatal myocardial infarction, hospitalization for unstable angina or arterial revascularization. Rosuvastatin reduced LDL-cholesterol levels by 50% and high-sensitivity C-reactive protein by 37%. Compared with placebo, the combined primary end point was reduced in 44% (p < 0.00001), and total mortality in 20% (p = 0.02). The trial confirmed the relationship between the rates of major cardiovascular events with both high-sensitivity C-reactive protein and LDL-cholesterol levels achieved after statin treatment. Interestingly, this was the first large, prospective statin trial to show benefit in the reduction of venous thromboembolism.
Indexed as
Identifiers
19764857What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.